IMPACT OF THERAPY WITH α-LIPOIC ACID (ALA) ON THE OXIDATIVE STRESS IN THE CONTROLLED NIDDM: A POSSIBLE PREVENTIVE WAY AGAINST THE ORGAN DYSFUNCTION?

被引:47
作者
Gianturco, V. [1 ]
Bellomo, A. [1 ]
D'Ottavio, E. [1 ]
Formosa, V. [1 ]
Iori, A. [1 ]
Mancinella, M. [1 ]
Troisi, G. [1 ]
Marigliano, V. [1 ]
机构
[1] Sapienza Univ Roma, Dipartimento Sci Invecchiamento, Umberto Policlin Roma 1, I-00161 Rome, Italy
关键词
alpha-lipoic acid; NIDDM-complications; total cholesterol; high-density lipoprotein-cholesterol; low-density lipoprotein-cholesterol; d-ROMs test; C-reactive protein; oxidative stress; SYMPTOMATIC DIABETIC POLYNEUROPATHY; NEUROPATHY;
D O I
10.1016/j.archger.2009.09.022
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
030301 [社会学]; 100201 [内科学];
摘要
There is a growing evidence that excess generation of highly reactive free radicals, largely due to hyperglycemia, causes oxidative stress, which further exacerbates the development and progression of diabetes and its complications. The purpose of this study was to evaluate the impact of ALA on lipid profile, oxidative pattern and inflammation in patients with controlled non-insulin dependent diabetes mellitus (NIDDM). ALA, 400 mg/day was investigated in NIDDM patients over a period of 4 weeks using a randomized, placebo-(PLA)-controlled study with two parallel groups. The marker of oxidative stress was the concentration of reactive oxygen metabolites, evaluated using a commercially available test, called d-ROMs test, and the biological antioxidant potential (BAP); besides, the lipid profile (total cholesterol = TC, high-density lipoprotein-cholesterol = HDL-C; low-density lipoprotein-cholesterol = LDL-C, and triglycerides = TG) and the C-reactive protein (CRP), marker of inflammation were measured at the beginning and at the end of the treatment. A total of 14 patients were randomly assigned to the two groups. ALA was safe and well tolerated in the only oral daily administration. The d-ROMs test (p = 0.03) and HDL-C (p = 0.04) showed a significant difference between the two groups. BAP (p = 0.06) tended to be higher in the treated patients, while LDL-C (p = 0.07) presented a moderate decline. There were no significant differences in TC (p = 0.65), TG (p = 0.78) and CRP (p = 0.96) between the ALA and PLA groups. ALA therapy appears to reduce significantly d-ROMs and to improve HDL-C value, especially in men with metabolic syndrome treated with oral hypoglycemic drugs. These findings will be useful in patient selection in future clinical trials with ALA in long term studies.
引用
收藏
页码:129 / 133
页数:5
相关论文
共 8 条
[1]
The sensory symptoms of diabetic polyneuropathy are improved with α-lipoic acid -: The SYDNEY trial [J].
Ametov, AS ;
Barinov, A ;
Dyck, PJ ;
Hermann, R ;
Kozlova, N ;
Litchy, WJ ;
Low, PA ;
Nehrdich, D ;
Novosadova, M ;
O'Brien, PC ;
Reljanovic, M ;
Samigullin, R ;
Schuette, K ;
Strokov, I ;
Tritschler, H ;
Wessel, K ;
Yakhno, N ;
Ziegler, D .
DIABETES CARE, 2003, 26 (03) :770-776
[2]
Biochemistry and molecular cell biology of diabetic complications [J].
Brownlee, M .
NATURE, 2001, 414 (6865) :813-820
[3]
Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (α-lipoic acid):: A two year multicenter randomized double-blind placebo-controlled trial (ALADIN II) [J].
Reljanovic, M ;
Reichel, G ;
Rett, K ;
Lobisch, M ;
Schuette, K ;
Möller, W ;
Tritschler, HJ ;
Mehnert, H .
FREE RADICAL RESEARCH, 1999, 31 (03) :171-179
[4]
THE EFFECT OF LONG-TERM INTENSIFIED INSULIN-TREATMENT ON THE DEVELOPMENT OF MICROVASCULAR COMPLICATIONS OF DIABETES-MELLITUS [J].
REICHARD, P ;
NILSSON, BY ;
ROSENQVIST, U .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (05) :304-309
[5]
Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid -: A 7-month multicenter randomized controlled trial (ALADIN III Study) [J].
Ziegler, D ;
Hanefeld, M ;
Rahnau, KJ ;
Hasche, H ;
Lobisch, M ;
Schütte, K ;
Kerum, G ;
Malessa, R .
DIABETES CARE, 1999, 22 (08) :1296-1301
[6]
Treatment of symptomatic diabetic polyneuropathy with the antioxidant α-lipoic acid:: a meta-analysis [J].
Ziegler, D ;
Nowak, H ;
Kempler, P ;
Vargha, P ;
Low, PA .
DIABETIC MEDICINE, 2004, 21 (02) :114-121
[7]
Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients - A 4-month randomized controlled multicenter trial (DEKAN study) [J].
Ziegler, D ;
Schatz, H ;
Conrad, F ;
Gries, FA ;
Ulrich, H ;
Reichel, G .
DIABETES CARE, 1997, 20 (03) :369-373
[8]
TREATMENT OF SYMPTOMATIC DIABETIC PERIPHERAL NEUROPATHY WITH THE ANTIOXIDANT ALPHA-LIPOIC ACID - A 3-WEEK MULTICENTER RANDOMIZED CONTROLLED TRIAL (ALADIN STUDY) [J].
ZIEGLER, D ;
HANEFELD, M ;
RUHNAU, KJ ;
MEISSNER, HP ;
LOBISCH, M ;
SCHUTTE, K ;
GRIES, FA ;
TICINELLI, EC ;
HAHNZOG, B ;
NEHRDICH, D ;
NETTEN, C ;
DANNEHL, K ;
PEUKERT, M ;
WESSEL, K ;
ANDERS, M ;
BRAUNING, H ;
BRUN, M ;
BRUNNER, E ;
VONBULTZINGSLOWEN, S ;
DONAUBAUER, B ;
FORCHHEIM, W ;
FUNKE, K ;
GERLACHENIYEW, S ;
HAMPEL, T ;
HANEFELD, M ;
HOCHE, I ;
HUNECKE, I ;
KLINKENSTEIN, C ;
VONKLITZING, KL ;
KLUTTIG, G ;
KONIG, I ;
KRAUSE, I ;
KRUGER, R ;
KUNZ, U ;
MANTZ, S ;
MARQUARDT, C ;
MENDE, M ;
MYRACHRAHN, A ;
RICHTER, E ;
RUTHE, WD ;
SAND, K ;
SCHUBERT, R ;
SCHULTZ, U ;
SEEBACHER, ML ;
SIMONSOHN, M ;
STOLL, M ;
STUNDEL, M ;
SZILLEWEIT, G ;
WALCH, O ;
WALZ, E .
DIABETOLOGIA, 1995, 38 (12) :1425-1433